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HIV infection and stroke: current perspectives and 
future directions
Laura A Benjamin, Alan Bryer, Hedley C A Emsley, Saye Khoo, Tom Solomon, Myles D Connor
HIV infection can result in stroke via several mechanisms, including opportunistic infection, vasculopathy, 
cardioembolism, and coagulopathy. However, the occurrence of stroke and HIV infection might often be coincidental. 
HIV-associated vasculopathy describes various cerebrovascular changes, including stenosis and aneurysm formation, 
vasculitis, and accelerated atherosclerosis, and might be caused directly or indirectly by HIV infection, although the 
mechanisms are controversial. HIV and associated infections contribute to chronic inﬂ ammation. Combination 
antiretroviral therapies (cART) are clearly beneﬁ cial, but can be atherogenic and could increase stroke risk. cART can 
prolong life, increasing the size of the ageing population at risk of stroke. Stroke management and prevention should 
include identiﬁ cation and treatment of the speciﬁ c cause of stroke and stroke risk factors, and judicious adjustment 
of the cART regimen. Epidemiological, clinical, biological, and autopsy studies of risk, the pathogenesis of HIV-
associated vasculopathy (particularly of arterial endothelial damage), the long-term eﬀ ects of cART, and ideal stroke 
treatment in patients with HIV are needed, as are antiretrovirals that are without vascular risk.
Introduction
The incidence of stroke has increased by 100% in middle-
to-low-income countries in the past 10 years.1,2 Although 
much of this increase is probably related to the increasing 
burden of vascular risk factors and the ageing population, 
infectious causes of stroke might also contribute.3,4 Low-
income and middle-income countries have the highest 
incidence of HIV infection,5 therefore occurrence of the 
two disorders in one patient might often be coincidental. 
However, HIV infection potentially aﬀ ects stroke risk 
and cause, and HIV treatment can result in vascular 
damage, perhaps conferring an additional risk.6,7
Between 1% and 5% of patients with HIV develop 
stroke in clinical series, although a higher proportion 
(4–34%) have cerebral ischaemic lesions at autopsy.8–14 
There was little correlation between pathological 
evidence of cerebral ischaemic lesions and clinical 
manifestations before death in series that assessed 
this.13,15 In the USA, admissions of patients with stroke 
and concurrent HIV infection have increased by 43% 
over 9 years.16 Despite this apparent association, 
surprisingly little research has assessed the eﬀ ect of HIV 
infection on the burden and nature of stroke, such as the 
extent to which HIV increases stroke risk, and the 
pathogenesis of stroke in individuals with HIV.6,17
Standard HIV treatment—combination antiretroviral 
therapy (cART)—might also contribute to the risk of 
stroke, directly by accelerating atherosclerosis and 
indirectly by increasing life expectancy.18 Inevitably, 
exposure to conventional vascular risk factors (eg, 
ageing, hypertension, diabetes, hypercholesterolaemia, 
and cigarette smoking) will continue to increase as 
the HIV population lives longer.19 Furthermore, the 
continuous exposure to HIV, albeit at lower viral titre, 
and low-grade chronic systemic inﬂ ammation might 
add to the risk of stroke.20,21
Assessment of the eﬀ ect of HIV infection on stroke has 
public health relevance, particularly with respect to the 
increased frequency of stroke in regions of high HIV 
prevalence. From a practical clinical perspective, when 
physicians in all regions are managing a patient with 
HIV who has had a stroke, they need to know the extent 
to which the HIV infection and its treatment might aﬀ ect 
the cause, clinical presentation, and man agement of the 
stroke, but they also need to consider that stroke might 
be the presenting feature of HIV infection in patients 
whose HIV status is not known.
In this Review we describe what is known about the 
risk of stroke in people infected with HIV. We present 
emerging theories of the mechanism of stroke in these 
patients and discuss the eﬀ ect of HIV on clinical stroke 
syndromes and implications for the management of 
stroke in HIV-infected patients.
HIV infection and the risk of stroke
Both HIV infection and cART could potentially increase 
an individual’s risk of stroke; therefore, any assessment 
of the risk attributable to HIV should ideally have been 
done in an untreated population. Most studies have been 
retrospective or have compared unmatched groups or 
cohorts or assessed the prevalence of HIV infection in 
stroke series compared with the general population of a 
similar age. Most have been hospital-based series, and 
some studies have compared cerebral infarction (rather 
than clinical stroke) in HIV-infected and HIV-unaﬀ ected 
brains at autopsy. No case-controlled or cohort studies 
have prospectively assessed the risk of stroke in HIV-
infected populations, and so the evidence for an increased 
risk with HIV infection is based on very little data.
Pre-cART era
A retrospective hospital-based case-control study com-
pared 113 patients aged 19–44 years who had had a stroke 
with 113 age-matched and sex-matched patients with 
asthma and known HIV status in the USA between 
1990 and 1994, and reported that HIV infection was 
associated with a doubling of the risk of stroke (odds 
ratio [OR] 2·3, 95% CI 1·0–5·3). The risk was higher for 
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cerebral infarction (OR 3·4, 95% CI 1·1–8·9) than for 
cerebral haemorrhage (OR 1·3, 95% CI 0·3–6·4). 
11 (44%) of 25 patients with HIV who had had a stroke 
had a coagulopathy (protein S deﬁ ciency) or meningitis.22 
A population-based study from Baltimore, MD, USA 
(1988–91) that identiﬁ ed 12 patients who had had a stroke 
and had AIDS (ascertained retrospectively) reported that 
AIDS conferred an adjusted relative risk of 13·7 (95% CI 
6·1–30·8) for ischaemic stroke and 25·5 (95% CI 
11·2–58·0) for cerebral haemorrhage.23 The selection of 
(by deﬁ nition) patients with advanced HIV infection who 
would therefore have a particularly high risk of stroke, 
and under-reporting of AIDS in the study population, 
might have resulted in the surprisingly high relative-risk 
ratios in this study.17
Not all studies have reported an association between 
HIV infection and stroke. A 1980’s autopsy study from 
the USA retrospectively compared the brains of patients 
aged 20–50 years with and without AIDS. Cerebrovascular 
disease was present in 13 (8%) of 154 patients with AIDS, 
and in a higher proportion (25 [23%] of 111) of controls, 
which suggested that stroke was not more common in 
patients with AIDS at autopsy.12 A hospital-based study 
in KwaZulu-Natal, South Africa, reported that the pre-
valence of HIV infection in a series of patients younger 
than 50 years who had had a stroke was 16%, similar to 
the prevalence of HIV in the general popu lation of a 
similar age.24 However, the extent to which this result 
can be generalised to the population of KwaZulu-Natal is 
unclear, because only 12% of patients with stroke 
included in the Durban Stroke Data Bank were black 
Africans, compared with a community proportion of 
85%.25 In a retrospective hospital-based study of 
293 black African patients with stroke aged 15–44 years 
from the same region as the previous study, HIV 
infection (present in 56) increased the risk of ischaemic 
stroke (OR 2·3, CI 0·8–7·7; p=0·09), although this 
ﬁ nding was not statistically signiﬁ cant.26 Patients with 
opportunistic infection were excluded from the study. 
However, HIV serology was not assessed in almost a 
third of patients.
Post-cART era
No studies have prospectively assessed the eﬀ ect of 
HIV infection on stroke risk since the introduction of 
cART.6,7 A retrospective analysis of hospital admission 
data for all individuals with HIV in Denmark (1995–2010) 
established the rate of cerebrovascular events and 
compared it with the rate in a sex-matched and age-
matched general population, stratiﬁ ed by intravenous 
drug use (IDU) and conventional vascular risk factors. 
Individuals with HIV had an increased risk of cerebro-
vascular events compared with controls (non-IDU HIV-
adjusted incidence rate ratio 1·60, 95% CI 1·32–1·94). 
Risk of cerebrovascular events increased when associated 
with IDU, low CD4 count before cART, and abacavir.27 
Although, arguably, this study provides the best evidence 
linking HIV with stroke risk, the retrospective nature of 
the study and absence of detailed prospective clinical 
assessment might have led to misclassiﬁ cation of 
cerebrovascular events in a population in which stroke 
mimics are common.
In a large US study that assessed population-
wide hospital stroke discharge diagnoses over 9 years 
(1997–2006), the number of patients with HIV admitted 
for stroke rose by 43%, after adjustment for population 
size. This increase was associated with a total increase in 
the proportion of patients who had an ischaemic stroke 
in the HIV population, and also coincided with the 
introduction of cART in the mid-1990s.16 How much of 
this rise was due to an increase in the incidence of HIV 
infection, to the eﬀ ect of cART on stroke risk in people 
with HIV, to an increased incidence of stroke in HIV-
positive individuals, to improved survival of those with 
HIV, or indeed to better recognition of stroke symptoms 
is impossible to tease out. How ever, the increase in HIV-
associated stroke admissions occurred at the same time 
as an overall (7%) reduction in all stroke admissions, 
suggesting, but not substantiating, an association 
between HIV infection and stroke.
Clinical presentation of stroke in patients 
with HIV
Age and stroke
Individuals with stroke who are HIV positive are reported 
to be younger than patients with stroke who do not have 
HIV, which could be a result of the age of the population 
at risk of HIV infection or a sign that the mechanism of 
stroke in HIV is largely independent of classical vascular 
risk factors. Ovbiagele and Nath16 reported a median age 
for individuals with HIV who had had a stroke of 
42·9 years in 1997 and 48·4 years in 2006 in the previously 
described retrospective analysis of hospital discharges in 
the USA, and Ortiz and col leagues28 reported a median 
age of 42 years in a similar setting between 1997 and 
2002. However, in lower-income countries such as South 
Africa and Malawi, patients with HIV who have strokes 
are younger—eg, in Cape Town, South Africa (2000–06) 
the median age was 33·4 years,29 and in Blantyre, Malawi 
(2008–09) it was 39·8 years.30 One possible explanation 
for this regional variation and the increase in median age 
seen in the USA over a decade might be the use of cART, 
perhaps because cART delays the time to stroke onset.
Clinical descriptions of stroke
Clinical descriptions of stroke in patients with and 
without HIV are similar.31–33 Although the sudden onset 
of a focal neurological deﬁ cit is typical, atypical stroke 
presentations are common in the context of HIV 
infection—eg, acute confusion, fever, acute loss of 
consciousness, and stepwise focal neurological pres-
entation over hours to days.34–36 Alternative causes or 
mimics of stroke should be excluded before a ﬁ nal 
diagnosis of HIV-associated stroke is made.
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Stroke type and subtype
Ischaemic stroke seems to be more frequent than 
cerebral haemorrhage in patients with HIV, at least in 
hospital-based series from sub-Saharan Africa, where it 
is reported in over 90% of HIV-associated strokes.28,33,37 
This trend was not supported by the scientiﬁ c literature 
from the pre-cART era in the USA, with near equal 
proportions of cerebral haemorrhage and ischaemic 
infarction in the Baltimore study described previously, 
although this result was probably due in part to illicit 
drug use or hospital-admission bias.23 However, 
Ovbiagele and Nath16 reported that ischaemic stroke was 
the predominant pathological stroke type and that the 
proportion of patients with ischaemic stroke among 
those with HIV doubled between 1997 and 2006.16 
Whether this rise is a result of cART or methodological 
factors is not clear.
In a South African hospital-based study, the subtypes of 
ischaemic stroke, classiﬁ ed according to Oxfordshire 
Community Stroke Project (OCSP) criteria, in the HIV-
positive group (n=64) were lacunar stroke (n=13), partial 
anterior circulation stroke (n=33), total anterior circu-
lation stroke (n=11), and posterior circulation stroke 
(n=7).29 The proportions of these subtypes follow similar 
trends to the original OCSP (lacunar stroke 25%, partial 
anterior circulation stroke 34%, total anterior circulation 
stroke 17%, and posterior circulation stroke 24%), but 
posterior circulation stroke was less frequent and partial 
anterior circulation stroke more frequent in this HIV 
population than in the OCSP, although this ﬁ nding was 
based on a small number of patients.38 However, the 
proportions of stroke type and subtype will only be 
determined accurately in a community-based HIV and 
stroke population because hospital admission favours 
cerebral haemorrhage.
Causes of stroke in patients with HIV
HIV infection can potentially cause stroke in many ways: 
indirectly through cardioembolism, coagulopathy, or 
non-HIV infective vasculitis; or directly through HIV-
associated vasculopathy. Panel 1 lists the mechanisms 
that might result in an ischaemic or haemorrhagic 
stroke.
Coagulopathy
HIV infection might predispose an individual to both 
arterial and venous thrombosis; however, to what extent 
this predisposition is caused by coagulopathy is unclear. 
Deﬁ ciencies in protein C and protein S are sometimes 
associated with intracranial venous thrombosis, but 
rarely with arterial stroke in adults without HIV.39,40 
Although deﬁ ciencies in protein C and protein S have 
been identiﬁ ed in HIV-infected patients who have had a 
stroke, whether these deﬁ ciencies are secondary events 
or caused directly by the HIV infection is unclear. In 
one South African case series in which patients with 
stroke and HIV infection (n=33) were compared with 
an unmatched group of patients with stroke who were 
not HIV-positive (n=33), the proportion of patients with 
protein S deﬁ ciency did not diﬀ er signiﬁ cantly between 
the groups.37
Antiphospholipid antibodies have been described in-
frequently in people with HIV who have had a stroke, 
but as transient raised antiphospholipid antibody titres 
are often reported with viral infection, raised concen-
trations should only be regarded as clinically relevant in 
patients meeting the International Haematology Con-
sensus statement criteria for antiphospholipid syn-
drome.41 These criteria have only rarely been applied in 
studies investigating stroke and HIV infection, and the 
true frequency of any association is unclear.33,42,43 
Factor V Leiden is not associated with HIV-related 
stroke.
Cardioembolism
Cardioembolism accounts for 4–15% of ischaemic strokes 
in people with HIV.24,28,42 HIV-associated dilated cardio-
myopathy is a frequently reported cause of cardiac disease, 
Panel 1: Possible HIV-related causes of stroke
Ischaemic
HIV-associated vasculopathy (abnormality of the cerebral blood 
vessels as a direct or indirect result of HIV infection, but excluding 
opportunistic infection vasculitis)
• Associated with aneurysm formation (either intracranial 
or extracranial)
• Vasculitis (as a direct result of HIV infection, excluding 
opportunistic infection)
• Accelerated atherosclerosis 
• Other disease of cerebral blood vessels associated with 
HIV infection (including small vessel disease changes and 
altered vasoreactivity)
Opportunistic infection or neoplasia
• Opportunistic infection causing stroke (eg, tuberculous 
meningitis, varicella zoster virus vasculitis, 
meningovascular syphilis)
• Neoplasia, such as lymphoma involving cerebral blood 
vessels
Cardioembolism
• Bacterial endocarditis
• Marantic endocarditis
• HIV-associated cardiac dysfunction 
• Ischaemic heart disease
Other established cause
• Coagulopathy (eg, antiphospholipid syndrome)
• HIV-associated hyperviscosity
Haemorrhagic
• HIV-associated vasculopathy (aneurysm or 
vasculitis-associated)
• HIV-associated thrombocytopenia
• Mycotic aneurysm (secondary to bacterial endocarditis)
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particularly in sub-Saharan Africa.44–46 This disorder might 
be associated with opportunistic infection and has been 
attributed to HIV itself, although its pathogenesis is 
uncertain. We have therefore used a deliberately vague 
term, HIV-associated cardiac dys function, in panel 1. 
Assessment of cardioembolic causes of stroke in patients 
with HIV in studies from sub-Saharan Africa is further 
complicated by the high preva lence of non-ischaemic 
cardiomyopathy and rheumatic heart disease in people 
without HIV.47 Other potential causes of cardioembolism 
include bacterial and marantic endocarditis, and 
ischaemic heart disease.48,49
Opportunistic infections
Some infections are well established causes of stroke. 
Mycobacterium tuberculosis, syphilis, and varicella zoster 
virus cause stroke in patients without HIV, but immuno-
suppression caused by HIV increases susceptibility to 
acquisition or reactivation of these infections.50–52 Tuber-
culosis-related stroke is thought to be a complication of 
tuberculous meningitis, and focal signs masquerading 
as stroke might be the ﬁ rst manifestation.50,53 Therefore, 
actively looking for tuberculosis in patients with HIV 
who have had a stroke (who are more at risk than those 
without HIV infection who have had a stroke) is 
important. Varicella zoster virus infection might cause 
cerebral vasculitis and stroke in immuno suppressed 
patients, although the skin manifestation can be absent 
at the time of presentation in about a third of patients 
with stroke, making diagnosis diﬃ  cult.51,54,55 Co-infection 
with HIV compounds the diagnosis of neurosyphilis, 
which is another potential cause of stroke.52,56 
Furthermore, an increase in meningovascular compli-
cations has been described in people with HIV.52,56,57
Cytomegalovirus and Candida albicans infections have 
been associated with HIV infection and stroke in a few 
case series, but further evidence is needed to establish 
whether they are a cause of stroke in HIV-infected 
patients.8,58 cART might unmask occult opportunistic 
infections that subsequently cause a stroke. This 
possibility should be considered in all patients who have 
had an acute stroke or have worsening of stroke 
symptoms after initiation of cART.58–61 Even in high-
income countries, opportunistic infection still leads to 
substantial mortality, despite the use of cART and good 
diagnostic facilities.60 Furthermore, infections outside 
the CNS might contribute to the development of a 
prothrombotic state, potentially in creasing the risk of 
ischaemic stroke.4
HIV-associated vasculopathy
HIV-associated vasculopathy is a relatively new and 
evolving term used to describe several arterial changes 
associated with HIV infection (ﬁ gure 1). Some inves-
tigators have distinguished aneurysmal arterial changes 
from vasculitis and others have suggested that in view of 
the uncertainty regarding the pathogenesis of vasculitis, 
all arterial abnormalities thought to be associated with 
stroke should be regarded as part of an HIV-associated 
vasculopathy. A working deﬁ nition would, in our opin ion, 
be useful to both clinicians and pathologists. On the basis 
of the current scientiﬁ c literature, we propose that the 
term HIV-associated vasculopathy should include any 
abnormality of the intracranial or extracranial cerebral 
blood vessels that results directly or indirectly from HIV 
B
A
C
Figure 1: Aneurysmal HIV-associated vasculopathy
(A) View of the ventral surface of the brain showing a thrombotic occlusion of 
the left internal carotid artery and evidence of vasculopathy of the left middle 
cerebral artery (arrows). (B) CT angiogram showing several fusiform aneurysms 
aﬀ ecting the circle of Willis. (C) Haematoxylin and eosin stain of a cross-section 
through an aneurysmal cerebral artery showing evidence of intimal hyperplasia, 
fragmentation of internal elastic lamina (arrow), and neutrophil inﬁ ltrate; note 
the absence of atherosclerosis. Reproduced from Tipping and colleagues,33 by 
permission of the American Medical Association.
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infection, but should exclude vasculitis associated with 
opportunistic infection or neoplastic involvement of the 
vessels (panel 1). Aneurysmal dilatation in HIV-infected 
patients can be extracranial, involving the carotid, aorta, 
iliac, and other large arteries, or intracranial, involving 
branches of the circle of Willis.62–64 In a series of patients 
with HIV and stroke (n=64), seven patients had an 
extracranial non-aneurysmal vascu lopathy that 
manifested as either stenosis or occlusion of the internal 
carotid artery. Autopsy of one of the individuals who died 
from complications associated with their stroke showed 
microscopic evidence of neovascular isation and vessel 
wall inﬂ ammation with a thrombus occluding the lumen. 
Six patients had radiological evidence of intracranial 
vasculopathy, typically involving the medium-sized 
vessels with or without fusiform aneurysm or stenosis. 
One patient’s histology showed luminal thrombosis, 
concentric intimal hyperplasia with hyalinisation, and 
fragmentation of the elastic lamina.29 In this case series, 
patients with an extracranial vascu lopathy had a 
signiﬁ cantly higher CD4 count compared with those with 
intracranial vasculopathy.29 Patients with HIV infection 
and stroke in this study were young (mean age 33·3 years) 
and did not have evidence of atherosclerosis.
In other studies, patients with HIV and extracranial 
carotid aneurysms (but without stroke) had evidence of 
leucocytoclastic vasculitis of the vasa vasorum and 
periadventitial vessels without evidence of atherosclerosis 
or infection on culture of the blood or aneurysm wall.63,65 
Whether this form of vasculitis is an initiating or pivotal 
event in the development of extracranial carotid artery 
aneurysm formation in HIV infection or is one of several 
factors is not clear. Fusiform intracranial cerebral an-
eurysms have been described in children, usually as 
incidental ﬁ ndings, but in some they are associated with 
subarachnoid haemorrhage or hemiparesis.66,67
The term vasculitis should ideally be reserved for the 
histologically conﬁ rmed appearance of inﬂ ammatory 
cells in the blood vessel wall together with associated wall 
damage. In early pathological studies that did not exclude 
all potential causes of infective vasculitis other than HIV, 
cerebral vasculitis attributed to HIV was probably over-
estimated.13,68 However, a heterogeneous array of extra-
cerebral vasculitis of small, medium, and large arteries 
has been described in patients with HIV.65 Although HIV 
antigen and particles were identiﬁ ed in perivascular cells 
in two patients, and HIV-like particles that were 
suggestive of a direct HIV infection (at least of perivascular 
tissue) have been reported in another, a direct role of HIV 
in the development of vasculitis is far from certain.65,69 
Other postulated mechanisms for vasculitis include 
immune deposition and indirect damage caused by T-cell-
derived growth factors and cytokines.65 In clinical practice, 
histology is seldom available and the diagnosis of cerebral 
vasculitis is usually based on clinical and radiological 
ﬁ ndings and exclusion of other possible causes. In several 
clinical case series, HIV-associated arterial vasculitis 
(attributable to opportunistic infection or other known 
cause) accounted for 13–28% of ischaemic stroke 
cases.28,29,42 In a patient presenting with clinical and 
radiological features typical of vasculitis, in whom all 
other probable causes have been excluded, HIV-associated 
vasculitis is the most reasonable diagnosis.
HIV infection can be associated with acceleration 
of large-vessel atherosclerosis, potentially caused by 
cART and associated metabolic complications such as 
dyslipidaemia, insulin resistance, or diabetes, by low-
grade chronic systemic inﬂ ammation, or by co-infections 
such as hepatitis C or cytomegalovirus.7,70 Interactions 
between co-infections and cART in the context of HIV 
might be more complex than appreciated. For example, 
mitochondrial genomics might play an important part in 
the development of metabolic disorders and cardio-
vascular diseases in patients taking cART who are co-
infected with HIV and hepatitis C virus.71 Little is known 
about the role of speciﬁ c co-infections in atherogenesis 
in individuals with HIV. The possible role of an 
infectious burden of several microorganisms (eg, 
Chlamydia pneumoniae, Helicobacter pylori, cytomegalo-
virus, herpes viruses 1 and 2), rather than individual co-
infections, should be considered, because this seems to 
be a relevant factor in the development of atherosclerosis 
in individuals without HIV.72
Other abnormalities of cerebral blood vessels such as 
altered vasoreactivity and small-vessel abnormalities 
have been described,7,13 but their importance in clinical 
stroke is not clear.
Other causes
Although arterial changes in patients with HIV might be 
associated with HIV or opportunistic infection (eg, 
varicella zoster virus or tuberculosis), other unrelated 
causes such as connective tissue disease and an arterial 
dissection should also be considered in this young 
population. Mycotic aneurysm resulting from bacterial 
endocarditis, HIV-induced thrombocytopenia, and com-
plications of aneurysmal and vasculitic HIV-associated 
vasculopathy might result in cerebral or subarachnoid 
haemorrhage (panel 1).
Pathogenesis of vasculopathy and 
atherogenesis in HIV
Much of our knowledge about the potential pathogenesis 
of HIV infection and stroke comes from experimental 
studies of in-vitro human brain microvascular endo thelial 
cells, human umbilical vascular endothelial cell models, 
and HIV-transgenic animal models.73–75 In-vivo studies in 
man have used various imaging modalities (eg, carotid 
and transcranial doppler, MRI, and angiography) to show 
endothelial integrity indirectly. Additionally, the use of 
circulating biomarkers has provided some insight into 
endothelial dysfunction in HIV infection.76
The vascular endothelium is a protective barrier, 
preventing arterial wall inﬂ ammation, coagulation, 
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remodelling, and ultimately, in some instances, stroke. 
Dysfunction of the endothelium is pivotal to the initiation 
and progression of vascular disease and might lead to 
occlusive thrombotic events mediated by leuco cyte 
recruitment, platelet adhesion and aggregation, blood-
clotting activation, and ﬁ brinolysis derange ment.73,77 This 
endothelium dysfunction underpins the inﬂ ammatory 
process of atherosclerosis, and similar eﬀ ects of 
endothelial  dysfunction have been reported in HIV 
experimental models and in individuals with stroke 
(ﬁ gure 2).77,78
Role of inﬂ ammation
Although HIV-1 is unlikely to be vasculotropic, the virus 
aﬀ ects endothelial homoeostasis and function in 
important ways that could initiate and propagate 
atherogenesis. The vascular endothelium is continually 
exposed to stimuli such as HIV-1-infected cells (CD4+ 
T cells, monocytes, and macrophages), freely circulating 
HIV-1 viruses, HIV-1 proteins (ie, TAT and GP120) that are 
released with host cell lysis or actively secreted, and viral-
induced proinﬂ ammatory cytokines.73,79 All these factors 
potentially activate the endothelium, damaging and 
increasing its permeability, and thereby assisting leucocyte 
invasion into the vessel wall and chronic inﬂ ammation.
HIV-1-induced cytokine endothelial activation might 
result in the production of reactive oxygen species, the 
expression of cell adhesion molecules (CAMs), and the 
release of chemoattractants at localised areas of vascular 
inﬂ ammation. Akin to the pathogenesis of athero sclerosis, 
chemoattractants such as chemokine ligand 2 (CCL2) 
might recruit leucocytes to the brain during HIV 
infection.80,81 CCL2 is also associated with an increase in 
HIV viral burden.82 Plasma concentrations of VCAM1, 
ICAM1, and E-selectin, in addition to other markers of 
inﬂ ammation (high-sensitivity C-reactive protein [hsCRP], 
interleukin 6, and the cystatins) are signiﬁ cantly  increased 
in HIV-1-positive patients compared with controls.73,83–85 
The activation of these biomarkers implicates HIV-1 virus 
in dysfunction of the endothelium and inﬂ am mation. 
Endothelial cell molecules involved in coagu lation, such 
as von Willebrand factor, thrombomodulin, plasminogen 
activator inhibitor-1 antigen, tissue factor, and d-dimer are 
deranged in HIV infection, favouring a prothrombotic 
state.84,85 Furthermore, some of these biomarkers of 
endothelial dysfunction and inﬂ ammation positively 
correlate with anti-p24 antibody concentrations and 
disease severity.84,86 This propagated inﬂ ammatory 
process could potentially accelerate atherosclerosis or 
independently initiate vascular disease.
A Direct damage
D Blood vessel occlusion
C Progression of damage and propagation
of atherogenesis
B Indirect damage
Exacerbated by vasculitis
A co-infective or a non-infective inﬂammatory  
process could underlie or be independent of an 
HIV-associated vasculopathy 
Exacerbated by cART
The eﬀect of HIV treatment could underlie
or be independent of HIV-associated 
vasculopathy; atherogenesis could be
exacerbated by the metabolic syndrome or 
endothelial damage or dysfunction
Endothelium Intimal layer Smooth muscle layer Adhesion molecule HIV virion Fibrin/thrombus
Leucocyte HIV-infected leucocyte Cytokines/chemokines Reactive oxygen species
Figure 2: Hypotheses on the mechanism of HIV-associated vasculopathy
Mechanisms are speciﬁ c to atheroma and potentially applicable to the other forms of HIV-associated vasculopathy. (A) Direct damage can occur through continuous 
exposure of the endothelium to HIV virion or viral particles (eg, GP120 or TAT) leading to endothelial dysfunction. (B) Indirect damage can arise from circulating 
infected monocytes freely transmigrating the endothelium as part of a normal surveillance, with an impaired reverse transmigration, thus increasing the 
subendothelial population of HIV infected monocytes. The release of chemokines such as CCL2 from infected leucocytes attracts more leucocytes. (C) Several events 
lead to the progression of damage and propagation of atherogenesis: upregulation of cell adhesion molecules (eg, selectins), leading to increased adhesion of 
infected or non-infected leucocytes; release of HIV virions into the arterial smooth muscle and continued active replication of the virus in smooth muscle cells; 
inﬂ ammatory cytokine release from HIV-infected cells, leading to further recruitment and adhesion of leucocytes, increased production of reactive oxygen species, 
and derangement of the coagulation system, favouring a prothrombotic state. Underlying this continuing process is the remodelling of the vessel wall, involving 
intimal hyperplasia and fragmentation of the elastic lamina. (D) Thrombotic occlusion of the vessel wall lumen is one of the outcomes of this process.
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Monocytes continually migrate from the bloodstream 
across the vascular endothelium for systemic immune 
surveillance and maintenance of macrophage popu-
lations in the brain. CD163 is a novel marker of activated 
monocytes. CD163 concentration is increased and asso-
ciated with non-calciﬁ ed coronary plaque in patients with 
HIV, suggesting a role in the pathogenesis of HIV-
associated atherogenesis.87 Monocytes can perform re-
verse transendothelial migration across the endothelium, 
necessary for the movement of tissue monocytes or 
macrophages back into the bloodstream. HIV-1-infected 
macrophages have a reduced capacity to emigrate from 
the subendothelial extracellular matrix in vitro, sug-
gesting that the infected monocyte can easily move from 
the blood to brain tissue, but not the reverse.88 Clinically, 
such an adaptation could promote the establishment of 
viral reservoirs and increase the exposure of HIV-1 and 
its viral proteins to the vessel wall. Since the vascular bed 
serves as the interface between the entry and exit of these 
monocytes, this could conceivably be where the greatest 
damage occurs. In the context of vascular disease, once 
the virus is subendothelial it can then infect coronary 
arterial smooth muscle in a manner dependent on CD4, 
chemokine, and endocytosis, and actively replicate in its 
new niche.80,89
Vessel wall remodelling
Animal models have shown a plausible link between 
endothelial dysfunction and vasculopathy. The well 
characterised so-called murine AIDS model of retroviral 
infection time-dependently decreased maximum aortic 
contractile responses and impaired endothelium-de-
pendent relaxation.90 Isolated aortas from infected mice 
also expressed higher concentrations of ICAM-1 and 
VCAM-1.75 These models also showed independent HIV-
associated vasculopathy.74,91 Thus, the murine AIDS 
model strongly suggests that retroviral infection, similar 
to that of HIV-1 in man, is capable of causing vascu-
lopathy and endothelial dysregulation in mice.
Some of these experimental ﬁ ndings have been 
corroborated in man. Brachial endothelium-dependent 
ﬂ ow-mediated dilatation and carotid intima-media 
thickness (cIMT) are functional and structural indicators 
of endothelial integrity, and when impaired and increased, 
respectively, are associated with immuno suppression or 
increasing HIV viral concentrations.92–94 Suppressed HIV 
replication is associated with less cIMT progression (a 
marker of subclinical atherosclesosis).95 Furthermore, 
thinning of the arterial media layer, a possible preclinical 
stage of HIV vasculopathy, has been reported.96
HIV-1-associated endothelial dysfunction probably 
compromises the CNS, although whether this results in 
hard clinical outcomes such as stroke is unclear. HIV 
could plausibly initiate injury to the vascular tree or 
contribute to further injury to an already damaged 
vascular tree caused by atherosclerosis, predisposing an 
individual to stroke.
Role of cART in the pathogenesis of 
cerebrovascular disease and stroke
Stroke risk is not only associated with HIV infection, but 
also with its treatment. cART could cause both direct 
tissue injury to arteries—resulting in raised concentration 
of markers of endothelial dysfunction—or indirectly 
cause injury through lipid modiﬁ cation;97 however, how 
relevant this is to cerebrovascular disease is still 
uncertain. An increase in the concentration of biomarkers 
indicating endothelial dysfunction should be interpreted 
with caution, as this increase could result from other 
factors—namely, autoreactive cell destruction by an 
improved autoimmune system or the ability of the 
therapy to destroy cells.
In the short term, cART might reduce the risk 
of ischaemic stroke and transient ischaemic attack, 
although this theory is based on retrospective data from 
only one study.98 However, evidence to suggest that long-
term cART results in endothelial toxicity and vascular 
dysfunction is increasing.83,98 Non-nucleotide reverse 
transcriptase inhibitors and protease inhibitors, but not 
nucleotide reverse transcriptase inhibitors, are thought 
to cause inﬂ ammation and might increase cardiovascular 
risk. Again, little is known about the eﬀ ect on cere-
brovascular risk. Abacavir, a nucleotide reverse tran-
scriptase inhibitor, has been associated with an increased 
concentration of hsCRP and interleukin 6, and in a 
retrospective cohort study, an increase in cerebrovascular 
events in people with HIV.27,79 However, a meta-analysis 
of published and unpublished randomised controlled 
trials did not support an increased risk of cardiovascular 
events with abacavir-containing cART regimens com-
pared with other cART. The extent to which these 
ﬁ ndings can be extrapolated to cerebrovascular disease is 
unknown.99 More research is needed, speciﬁ cally with 
cerebrovascular events as an endpoint.
cART does not stop HIV-related endothelial dys-
function and inﬂ ammation. Ross and colleagues83 
showed enhanced endothelial activation, inﬂ ammation, 
and increased cIMT in patients with HIV taking cART, 
concluding that although cART does reduce the 
virulence of HIV, it has little anti-inﬂ ammatory potential 
on the endothelium. Therefore, individuals with HIV 
receiving cART are likely to live longer, but with long-
term endothelial and metabolic challenges, increasing 
stroke risk.
Management
Stroke mimics are not uncommon in people with HIV. 
Of the 98 consecutive patients presenting with an acute 
focal neurological deﬁ cit in Malawi, 11 were reported to 
have another cause for their presentation (eg, toxoplas-
mosis, neurocysticercosis, tuberculoma, brain tumour).31 
Brain imaging in patients with HIV presenting with 
sudden-onset focal signs and features suggestive of stroke 
is therefore essential for diagnosis and to dis tinguish 
between cerebral haemorrhage and ischaemic stroke.
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Once a diagnosis of stroke is veriﬁ ed, management 
should be directed towards acute stroke treatment, 
establishment of the cause of the stroke, management 
of HIV infection, and secondary prevention of stroke. 
Concomitant HIV infection raises doubt about extrapo-
lation from evidence-based treatment of non-HIV-related 
stroke. The role of intravenous thrombolysis is uncertain 
in the absence of randomised controlled studies in HIV-
related stroke. Often, the patient’s HIV status is not 
known at the time of presentation of acute stroke, and the 
decision of whether to give thrombolysis must be made 
within a short timeframe. Although no clear evidence of 
harm exists, and individuals with HIV might well have a 
stroke that is unrelated to HIV infection, the pathogenesis 
of stroke can include HIV-associated vasculopathy, 
infective vasculitis, infective meningitis, and other causes 
that might increase bleeding risk (panel 1). Reassuringly, 
isolated reports of successful use of thrombolysis to treat 
myocardial infarction in individuals with HIV are 
available.100 However, the extent to which these ﬁ ndings 
can be generalised to patients with potentially diseased 
cerebral vessels and higher bleeding risk with 
Blood test
• Test for FBC, glucose, urea and electrolytes, 
 cholesterol, CD4 count, ESR, ANA, and ANCA
• Infection screen (serology/PCR/antigen test) for 
 causes of vasculitis or stroke mimics. Test for 
 syphilis, toxoplasma, cryptococcus, HSV-1, VZV, 
 CMV, and bacterial or TB blood culture if clinically 
 indicated
• Coagulation screen for antiphospholipid antibodies
Lumbar puncture 
As listed in essential investigations box plus 
additional viral studies (HSV-1 and CMV PCR) if 
patient has suspected vasculitic HIV-associated 
vasculopathy
Chest radiograph
Look speciﬁcally for: infection, particularly 
tuberculosis, and tumours; cardiac disease, which 
could result in emboli; and blood vessel 
abnormalities (eg, Takayasu’s arteritis)
Cerebral haemorrhage
Exclude HIV-associated causes 
(table 1)
Ischaemic stroke
Additional tests
ECG; bubble-contrast 
echocardiogram; carotid 
Doppler; angiography
Admit to a stroke unit
• Treat reversible causes appropriately  
• Consider appropriate secondary preventative therapies
• Begin cART if infective causes have been excluded
Large-vessel atherosclerosis, 
HIV-associated vasculopathy, 
or small-vessel disease
Cardioembolism Other HIV-associated 
causes (table 1)
History and examination
Assess vascular risk factors (eg, hypertension, 
diabetes, smoking history, previous TIA, previous 
stroke, recent infection, hypercholesterolaemia); 
assess risk factors related to HIV infection (eg, illicit 
drug use, shingles, tuberculosis, and cART) 
Brain imaging
After clinical diagnosis of stroke, undertake brain 
imaging to exclude mimics and establish type of 
stroke
Clinically diagnosed 
stroke or TIA
HIV-positive Essential investigations (if brain CT is available)
• Blood test for FBC, urea and electrolytes, glucose, 
 cholesterol (particularly if the patient is taking 
 antiretroviral drugs), CD4 count, syphilis serology, 
 and blood cultures (if infective endocarditis is 
 possible). For cerebral haemorrhage add partial 
 thromboplastin time and prothrombin time or 
 international normalised ratio
• Chest radiograph
• Lumbar puncture (if no contraindication and no 
 clear evidence of an alternative cause—eg, 
 cardioembolic source) consisting of microscopy, 
 Gram stain, culture, acid-fast bacilli and 
TB culture, protein and glucose concentrations, 
and assessment for syphilis, cryptococcus, and
(if available) toxoplasmosis and VZV
+
Figure 3: Management approach for HIV-infected patients with stroke
TIA=transient ischaemic attack. cART=combined antiretroviral therapy. FBC=full blood count. ESR=erythrocyte sedimentation rate. ANA=antinuclear antibodies. 
ANCA=antineutrophil cytoplasmic antibodies. HSV-1=herpes simplex virus type 1. VZV=varicella zoster virus. CMV=cytomegalovirus. TB=tuberculosis. 
ECG=electrocardiograph.
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thrombolysis is unclear. Until such data become available, 
acute therapy, including the use of thrombolysis, will 
have to be decided on an individual basis, taking into 
account clinical judgment and patient choice.
Investigation should be directed at assessment for 
conventional causes of stroke and causes associated 
with HIV (described above and in ﬁ gure 3), with 
particular emphasis on the identiﬁ cation of treatable 
causes. The approach to management outlined in 
ﬁ gure 3 will not be possible in many areas where HIV 
infection is prevalent. In low-resource settings, 
investigation and treatment should be directed at 
identiﬁ cation of treatable causes of stroke or stroke 
mimics, such as tuberculosis, crypto coccus, 
toxoplasmosis, varicella zoster, or herpes virus 
infection, perhaps by combining CT brain scan, chest 
radiograph, lumbar puncture (if not contraindicated 
and in the absence of an alternative cause—eg, an 
obvious cardioembolic source), and selected blood tests 
(ﬁ gure 3). Ancillary tests might be needed to establish 
the cause of stroke (eg, sputum and CSF samples for 
tubercu losis).101,102 Measuring intrathecal IgG against 
varicella zoster virus together with CSF DNA PCR 
improves the likelihood of identifying this potential 
cause.54 Diagnosis of neurosyphilis in patients with 
HIV can be complex.  A positive CSF venereal disease 
research laboratory test can help—when this test is 
negative in a patient with HIV, a test for CSF treponemal 
antibodies seems a reasonable approach.52,103
Antineutrophil cytoplasmic antibodies (ANCA) assessed 
by immunoﬂ uorescence and enzyme-linked immuno-
sorbent assay have been identiﬁ ed in patients with HIV, 
but not necessarily in patients with vasculitis, 
autoimmune disease, or speciﬁ c opportunistic infec-
tion.104–106 Diagnosis of cerebral vasculitis in patients with 
HIV should be based on the results of appropriate 
radiological and, if possible, histological features, without 
the presence of any other potential cause of vasculitis (eg, 
opportunistic infection). In this setting, detection of 
ANCA might strengthen the diagnosis.
In high-resource settings, investigation should include 
detailed assessment of cerebral arteries with carotid 
doppler and CT, or magnetic resonance angiography, 
depending on local skills. In selected patients, perhaps 
those who have had further events or have a comorbidity 
suggesting autoimmune or other disease, conventional 
angiography or brain biopsy might be indicated. In low-
resource settings without access to brain imaging, we 
advise basic stroke care with the approach outlined in the 
South African stroke guideline.107
The role of immunosuppression with corticosteroids is 
far from clear.32,36 In the absence of any evidence to guide 
management, it seems reasonable to introduce cART 
(with a corticosteroid if the patient has a poor response) 
if vasculitic HIV-associated vasculopathy is suspected 
and other potential autoimmune or infectious causes 
have been excluded.
Evidence has convincingly shown that cART results in 
a reduction of all-cause mortality in patients with 
HIV.108,109 Far less certain is whether cART treatment, 
particularly exposure to protease inhibitors, increases the 
long-term risk of stroke and myocardial infarction as a 
result of metabolic eﬀ ects (eg, hypercholesterolaemia, 
already described) and extended survival (ageing is a risk 
factor for stroke and some populations infected with HIV 
have a high prevalence of cigarette smoking).109–111 The 
Panel 2: Future directions and research priorities in HIV 
and stroke
Epidemiological, pathological, and clinical
• Community-based epidemiology in low-income and 
high-income regions with detailed clinical assessment of 
stroke patients; early brain imaging; clearly documented 
stroke types and subtypes; assessment of risk factors and 
causes; autopsy conﬁ rmation or exclusion of stroke and 
identiﬁ cation of cause of stroke; assessment of the 
long-term eﬀ ect of combined antiretroviral therapy 
(cART)
• Community-based case control studies to assess risk of 
stroke associated with HIV infection
• Assessment of risk and causes of recurrent stroke in 
patients with HIV-related stroke
• Outcome of thrombolysis treatment in patients with HIV 
infection who have had a stroke
• Post-mortem and biopsy evidence in particular to better 
deﬁ ne the nature of all forms of HIV-associated 
vasculopathy in stroke
• Assessment of the eﬀ ect of HIV clades (or subtypes) on 
clinical presentation of stroke and HIV-related vascular 
disease
• Assessment of the eﬀ ect of cofactors related to the mode 
of HIV transmission, such as associated intravenous drug 
misuse, on stroke cause and presentation
Establishing pathogenesis and pathophysiology
• Assessment of the eﬀ ect of HIV infection and cART on the 
cerebral vascular endothelium (biological and mechanistic 
studies)
• Development of improved, ideally simple and cost-
eﬀ ective, diagnostic techniques to test for opportunistic 
infections associated with stroke in patients with HIV
• Assessment of the eﬀ ect of infection burden (HIV and 
opportunistic infection) on accelerated atherosclerosis 
(deep sequencing methods to identify unknown 
pathogens)119
Treatment
• Development and assessment of optimum treatment 
strategies for management of stroke risk factors in 
patients on cART
• Development of antiretroviral therapy without the 
metabolic and endothelial eﬀ ects of current drugs 
(provided it is as eﬀ ective as current therapy)
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risk–beneﬁ t ratio of cART based on current knowledge 
seems to be favourable. However, in view of the concern 
about long-term stroke and cardiovascular disease risk, a 
pragmatic approach seems reasonable—ie, physicians 
should identify and manage risk factors, perhaps change 
the class of cART regimen, or consider a cholesterol-
lowering drug if appropriate.108,109,112–114
None of the studies that guide the use of secondary 
prevention for stroke, including use of antiplatelets, 
statins, and blood-pressure-lowering therapy, can be 
directly extrapolated to patients with HIV who have had 
a stroke. However, general lifestyle factors and 
reduction of vascular risk factors seems sensible. 
Finally, the mode of HIV infection relevant to the 
patient should be considered, because this might aﬀ ect 
underlying stroke risk factors, cause, and management. 
In sub-Saharan Africa, the major mode of HIV 
transmission is sexual intercourse among hetero-
sexuals, whereas transmission via IDU is rare.115,116 
However, a history of IDU use is relevant, particuarly in 
areas where it is common, because it might be 
associated with several potential causes of stroke, 
includ ing the use of speciﬁ c drugs (cocaine, 
amphetamines, sympathomimetic drugs), infective 
endocarditis, and embolisation of particulate matter.117 
In many regions, cigarette smoking is more common 
in people with HIV than in the general population.118
Conclusions and future directions
Good community-based epidemiology to assess the 
burden and nature of HIV-related stroke is rare. 
Epidemiological studies with good clinical assessment of 
stroke patients, early imaging, clearly documented stroke 
types, subtypes, risk factors and causes, and importantly 
autopsy conﬁ rmation or exclusion of stroke and 
identiﬁ cation of the underlying cause of stroke, are 
needed in both high-income and low-income regions 
(panel 2). Improved knowledge about the mechanisms 
and causes of stroke should lead to improved inves-
tigation and treatment of patients. Further study is 
needed to assess the beneﬁ t and safety of acute stroke 
therapy and secondary stroke prevention in patients with 
HIV. Finally, the long-term eﬀ ect of cART on stroke 
incidence is also unknown, and it might take years to 
establish this risk. 
Stroke is increasing in low-income and middle-
income countries, and HIV infection—often prevalent in 
resource-poor regions—might add to this risk, although 
data are very scarce. Although cART might decrease 
stroke risk in the short term, its eﬀ ect on the vasculature 
and long-term stroke risk is unknown, but could be 
substantial. Certainly, cART has increased the lifespan of 
those infected with HIV, but paradoxically it might 
increase their risk of stroke in the long term, as a result 
of endothelial and metabolic side-eﬀ ects. The risk of 
stroke in patients with HIV and the need for further 
research to clarify burden, causes, pathogenesis, and 
management continues in areas with little or inadequate 
antiretroviral therapy. Equally, the need exists in high-
income regions with patients on long-term antiretroviral 
therapy (ie, cART). The added stroke burden to patients 
and health services in all regions might only be realised 
in future decades.
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